ArticleClinical, cosmetic and investigational dermatology2026
HEXB as a Candidate Target Gene in Keloid Radiotherapy: Based on Multi-Omics Analysis and Mendelian Randomization.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Keloid is a common and treatment-refractory conditions in plastic surgery and dermatology. Although radiotherapy for keloid has attracted increasing attention in recent years, its mechanism at the genetic level remains poorly characterized. This study investigated the relationship between radiation-related genes (RRGs) and keloid through an integrated multi-omics and machine learning framework, and to explore potential therapeutic agents targeting the identified key gene. Methods: Single-cell RNA sequencing and multiple Gene Expression Omnibus (GEO) datasets were integrated to investigate the association between RRGs and keloid. Multiple machine learning algorithms were applied to assess potential causal relationships, followed by Mendelian randomization (MR) analysis to investigate potential relationships. Spatial transcriptomics was employed to localize gene expression within keloid tissue, and virtual knockout analysis was performed to assess the functional role of the candidate gene in tissue architecture. Finally, molecular docking was conducted to screen potential therapeutic agents targeting HEXB, and molecular dynamics (MD) simulations were performed to evaluate the stability of the resulting protein-ligand complexes. Results: Hexosaminidase Subunit Beta (HEXB) was identified as a key gene. MR analysis further provided genetic evidence supporting a potential protective association between HEXB and keloid, identifying HEXB as a candidate protective gene. Spatial transcriptomics localized HEXB to the fibrotic dermal matrix with intralesional heterogeneity, while virtual knockout analysis implicated HEXB in maintaining epidermal-mesenchymal boundary integrity. Molecular docking demonstrated that HEXB predicted binding to several drugs, such as tamoxifen and estramustine, suggesting that HEXB may serve as a key target of these agents in keloid treatment. Conclusion: This study identifies HEXB as a candidate protective gene in keloid through an integrated multi-omics approach and suggests that HEXB may serve as a molecular target for potential therapeutic agents. These findings provide new directions for understanding the molecular mechanisms underlying radiotherapy in keloid and for developing targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.